Can Pfizer’s $10.5bn Innovent deal rebuild confidence in its oncology pipeline?
Pfizer’s $10.5bn Innovent deal targets ADCs and multispecific antibodies. Find out why China biotech is reshaping oncology pipelines.
Why Pfizer’s $10.5bn Innovent Biologics deal matters for the next wave of cancer medicines
Pfizer’s $10.5bn Innovent alliance deepens its oncology reset. Can early ADC and multispecific bets become global cancer drugs?
What Biomolecular Holdings LLC’s platform patents reveal about the future of antibody engineering
Biomolecular Holdings LLC secures platform patents for tetrahedral antibodies. Discover what this means for the future of antibody engineering.
Can Harbour BioMed’s deal with Bristol Myers Squibb redefine the future of multispecific antibodies?
Harbour BioMed has signed a global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multispecific antibodies. The deal could be worth over $1.1 billion across upfront payments, milestones, and royalties. It also signals growing interest in platforms capable of generating novel immunotherapies for complex diseases. The announcement is not […]